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ABSTRACT
Killer cell immunoglobulin-like receptors (KIRs) play an important role in the activation of natural killer (NK) cells, which in
turn contribute to the effective immune control of many viral infections. In the context of HIV infection, the closely related
KIR3DL1 and KIR3DS1molecules, in particular, have been associated with disease outcome. Inhibitory signals via KIR3DL1 are
disrupted by downregulation of HLA class I ligands on the infected cell surface and can also be impacted by changes in the pre-
sented peptide repertoire. In contrast, the activatory ligands for KIR3DS1 remain obscure. We used a structure-driven approach
to define the characteristics of HLA class I-restricted peptides that interact with KIR3DL1 and KIR3DS1. In the case of HLA-
B*57:01, we used this knowledge to identify bona fide HIV-derived peptide epitopes with similar properties. Two such peptides
facilitated productive interactions between HLA-B*57:01 and KIR3DS1. These data reveal the presence of KIR3DS1 ligands
within the HIV-specific peptide repertoire presented by a protective HLA class I allotype, thereby enhancing our mechanistic
understanding of the processes that enable NK cells to impact disease outcome.
IMPORTANCE
Natural killer (NK) cells are implicated as determinants of immune control in many viral infections, but the precise molecular
mechanisms that initiate and control these responses are unclear. The activating receptor KIR3DS1 in combination with HLA-
Bw4 has been associated with better outcomes in HIV infection. However, evidence of a direct interaction between these mole-
cules is lacking. In this study, we demonstrate that KIR3DS1 recognition of HLA-Bw4 is peptide dependent. We also identify
HIV-derived peptide epitopes presented by the protective HLA-B*57:01 allotype that facilitate productive interactions with
KIR3DS1. Collectively, these findings suggest a mechanism whereby changes in the peptide repertoire associated with viral infec-
tion provide a trigger for KIR3DS1 engagement and NK cell activation.
The role of natural killer (NK) cells and ofmembers of the killercell immunoglobulin-like receptor (KIR) family in the control
of viral infections is supported by a growing body of evidence from
functional analyses and disease association studies. Particular
KIRs have been implicated in the immune response to several
persistent viruses, including human cytomegalovirus (HCMV),
hepatitis C virus (HCV), human papillomavirus (HPV), and hu-
man immunodeficiency virus (HIV) (reviewed in reference 1). In
the context of HIV, specific KIR genes, KIR/HLA combinations,
and/or variations in KIR gene copy numbers have been linked
with resistance to infection (2, 3), disease progression (4–6), and
the development of opportunistic infections (7). In addition,
functional experiments have demonstrated KIR/HLA-dependent
NK cell expansion and cytotoxicity in relation to the control of
viral replication (8–10). Nonetheless, the mechanistic basis for
these observations remains obscure.
Members of the KIR family include both activating and inhib-
itory receptors expressed on the surface of NK cells and various T
cell subsets (reviewed in reference 11). In each case, ligand recog-
nition ismediated by either two (2D) or three (3D) extracellular Ig
domains. Inhibitory KIRs possess a long (L) cytoplasmic tail
containing immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) responsible for the transduction of a negative signal via
recruitment of protein tyrosine phosphatases. In contrast, activat-
ing KIRs harbor a charged residue in the transmembrane domain
together with a short cytoplasmic tail (S) and couple to the signal-
ing adaptor DAP12.
The best-described KIR ligands are HLA class I molecules. KIR
binding is focused on the 1 and 2 domains of the HLA mole-
cule, and position 80 of the heavy chain has been shown to be a key
specificity determinant for multiple KIRs (12–14). KIR3DL1
binds specifically toHLA-A andHLA-Bmolecules that possess the
Bw4 public epitope (15). These interactions are modulated by the
presented peptide, most notably via specific residues at the C ter-
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minus (12, 16). Consequently, NK cells can be sensitive to changes
in the peptide repertoire even when HLA expression levels are
maintained. In contrast, the role of activating KIRs is less well
understood. Although several activating KIRs are very similar at
the sequence level to their inhibitory counterparts (e.g., 2DL1/
2DS1 and 3DL1/3DS1), evidence of HLA binding has been much
more difficult to detect. For example, biochemical and functional
analyses have shown that KIR2DS1 binds to HLA-C2 complexes
with affinities that lie well below those observed for KIR2DL1
(17). This reducedHLAbinding has been attributed to single KIR-
specific amino acid polymorphisms (18–20), which appear to
leave peptide preferences largely intact (17).
KIR3DS1 is the activating counterpart of KIR3DL1, exhibiting
97% amino acid similarity in extracellular domain. In a study of
HIV-infected individuals,Martin et al. demonstrated that carriage
of theKIR3DS1 gene in conjunctionwith a subgroup ofHLA-Bw4
(Bw4 80I) alleles was associated with slower progression to AIDS
(21). Subsequent functional experiments revealed that NK cells
from individuals with this compound genotype displayed higher
levels of degranulation andwere able to controlHIV replication in
autologous CD4 T cells (8). Analysis of KIR3DS1 expression in
HIV-infected patients further showed that KIR3DS1 NK cell
subsets expand during acute infection, most markedly in individ-
uals with HLA-Bw4 80I (9). These results suggest an important
combined role for KIR3DS1 and HLA-Bw4 80I in the immune
response to HIV infection. However, in the absence of direct evi-
dence for an interaction between KIR3DS1 and Bw4 80I allotypes,
a mechanistic basis for genetic association has been lacking (8, 22,
23). Analysis of the amino acid differences between KIR3DL1 and
KIR3DS1 reveals four key residues that may critically govern the
differential HLA-Bw4 binding patterns of these closely related re-
ceptors; in each case, the KIR3DS1-like variant has been individ-
ually implicated as a determinant of reduced affinity for HLA (12,
24, 25). In contrast, a single amino acid change is responsible for
the impaired HLA affinity of 2DS KIRs. It therefore seems feasible
that KIR3DS1 may display unique specificities, either in terms of
HLA recognition and/or peptide tolerance.
It is established that KIR interactions with HLA class I mole-
cules are sensitive to changes in the presented peptide, especially at
the C terminus (12). The ability to discriminate between peptides
can also control NK cell activity (26). In this study, we used a
structure-driven approach to characterize specific peptide prefer-
ences and identify HLA-Bw4-restricted ligands recognized by
KIR3DS1.
MATERIALS AND METHODS
Cell lines.HEK293T cellsweremaintained inDulbecco’smodifiedEagle’s
medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM
L-glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin. Jurkat cells
stably expressing chimeric KIR3DS1-CD3 reporter constructs (22) were
maintained in RPMI medium supplemented with 10% FCS, 2 mM L-glu-
tamine, 50 U/ml penicillin, 50g/ml streptomycin, and 0.5 mg/ml Gene-
ticin. Ba/F3 cells were maintained in RPMI medium supplemented with
10% FCS, 2 mM L-glutamine, 50 U/ml penicillin, 50g/ml streptomycin,
and 10 ng/ml murine interleukin-3 (mIL-3).
Mutagenesis and transfection studies. KIR3DL1 and KIR3DS1 con-
structs with a 5= FLAG tag sequence (GACTACAAAGACGATGACGAC
AAG) were cloned into a pEF6 vector. Specific nucleotide residues were
mutated using aQuikChange II site-directedmutagenesis kit (Stratagene)
with PAGE-purified primers and verified by direct sequencing. These
constructs were introduced into HEK293T cells using FuGene6 transfec-
tion reagent (Roche) according to the manufacturer’s instructions.
Tetramer staining. Fluorochrome-conjugated peptide-HLA (pHLA)
class I tetramers (detailed in Table 1) were produced as described previ-
ously (27). Cells were stained at 48 h posttransfection with an optimal
concentration of tetramer (0.2g with respect to themonomeric compo-
nent in minimal residual volume) or anti-FLAG (clone M2; Sigma-Al-
drich) monoclonal antibody (MAb) for 30 min at 4°C. In all cases, mock-
transfected HEK293T cells were stained in parallel to identify any
background staining. Ba/F3 cells stably expressing LILRB1 were used as a
positive control for tetramer fidelity. For blocking experiments, cells were
preincubated with the indicated MAb (10 g/ml) for 15 min at 4°C.
Reporter assays. Jurkat cells stably expressing chimeric KIR3DS1-
CD3 reporter constructs (22) were transiently transfected with an NFAT
(nuclear factor of activated T cells)-luciferase plasmid by electroporation
and then stimulated with plate-bound HLA class I monomer for 18 h at
37°C. Luciferase activity was measured after cell lysis using a Dual-Glo
luciferase assay (Promega).
Crystallization and data collection. The HLA class I heavy chain and
2-microglobulin were refolded from inclusion body preparations ex-
pressed in Escherichia coli and purified as detailed previously (28).
KIR3DL1*001 was expressed in HEK293S cells and purified from the se-
creted fraction by nickel affinity and size exclusion chromatography. The
HLA-B*57:01-LF9.A8 (where LF9.A8 indicates the nine-residue peptide
beginning with an L residue and ending with an F residue and with a
substitution of an A residue at position 8, i.e., LSSPVTKAF) and HLA-
B*57:01-LF9.E8 (LSSPVTKEF) binary complexes were concentrated to
12 mg/ml in 10 mM Tris, pH 8.0. The ternary KIR3DL1*001-HLA-
B*57:01-LF9.A8 complex was concentrated to10mg/ml in 10mMTris,
pH 8.0, and 300 mM NaCl. Crystals were obtained at 294 K by the hang-
ing-drop vapor diffusion method. Binary complexes were crystallized
from a reservoir solution comprising 28% polyethylene glycol (PEG)
8000, 0.2 M ammonium sulfate, and 0.1 M cacodylate, pH 6.25 (29). The
ternary complex was crystallized from a reservoir solution comprising
16% PEG 3350, 0.1 M tri-sodium citrate, pH 6.0, and 4% Tacsimate, pH
5.0 (12). Prior to data collection, binary crystals were equilibrated in a
crystallization solution with 10% glycerol added as a cryoprotectant and
then flash cooled in a stream of liquid nitrogen at 100 K. The ternary
crystals were similarly flash cooled in a cryoprotectant composed of res-
TABLE 1 The peptide sequences and HLA molecules used to generate
pHLA complexes in this study
Name HLA Peptide Peptide source
LF9 B*57:01 LSSPVTKSF Human
LF9 A8 B*57:01 LSSPVTKAF Modified from human
LF9 E8 B*57:01 LSSPVTKEF Modified from human
LF9 F8 B*57:01 LSSPVTKFF Modified from human
LF9 H8 B*57:01 LSSPVTKHF Modified from human
LF9 L8 B*57:01 LSSPVTKLF Modified from human
LF9 R8 B*57:01 LSSPVTKRF Modified from human
TW10 B*57:01 TSTLQEQIGW HIV
TW10 G9D B*57:01 TSTLQEQIDW HIV
RW8 A*24:02 RYPLTFGW HIV
RW8 W8A A*24:02 RYPLTFGA HIV
RW8 Y2F A*24:02 RFPLTFAW HIV
IF9 B*57:01 ISGKAKGWF HIV
KY10 B*57:01 KAVRIKLFLY HIV
AL9 B*57:01 AAFDLSFFL HIV
ISY B*57:01 ISYIMLIFF Yellow fever virus
AW9 B*57:01 AAVKAACWW HIV
KF9 B*57:01 KAAFDLSFF HIV
RW9 B*57:01 RTIQGQRFW Bacillus anthracis
YF9 B*57:01 YPASLHKFF Marburg virus
O’Connor et al.
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ervoir solution supplemented with 35% PEG 3350. X-ray diffraction data
were recorded on a Quantum-315 charge-coupled device (CCD) detector
at theMX2 beamline of the Australian Synchrotron. Data were integrated
and scaled using MOSFLM and SCALA from the CCP4 program suite
(30). Details of the data processing statistics are provided in Table 2.
Structure determination and refinement. Structures were deter-
mined by molecular replacement as implemented in Phaser (31). The
searchmodel used for the ternary complex was the previously determined
structure of KIR3DL1*001-HLA-B*57:01-LF9 (Protein Data Bank [PDB]
accession code 3VH8). The search model used for the binary complexes
was the previously determined structure ofHLA-B*57:01with the peptide
removed (PDB accession code 3VH8) (29).Model refinement was carried
out in PHENIX (32) with iterative rounds of manual building in COOT
(33). Solvent molecules were added with COOT, and the structures were
validated with MolProbity (34). The final refinement values are summa-
rized in Table 2. The KIR3DS1-HLA-B*57:01-LF9 ternary complex was
modeled on the KIR3DL1*001-HLA-B*57:01-LF9 crystal structure (PDB
accession code 3VH8) (12). The substitutions I47V, S58G, V92M,
G138W, P163S, L166R, and P198L were generated and manually fitted in
COOT (33). The model was energetically minimized with geometry re-
straints in REFMAC (35).
Statistical analysis. One-way analysis of variance (ANOVA) with
Dunnett’s multiple comparison posttest was performed using GraphPad
Prism, version 5.0a, for Mac OS X (GraphPad Software, San Diego,
CA, USA).
RESULTS
KIR3DL1 recognition is influenced by HLA-B*57:01-LF9 pep-
tide variants. It is established that C-terminal peptide residues in
the pHLA complex critically impact KIR3DL1 recognition (12, 16,
36, 37). For example, in the context ofHLA-B*57:01 bound to LF9
(LSSPVTKSF), replacing the serine (S) at position 8 (P8) with the
negatively charged residue glutamate (E) or the smaller, nonpolar
residue alanine (A) dramatically reduced binding to KIR3DL1
(12). Such peptide modifications could affect KIR3DL1 binding
directly by disrupting interactions with the KIR molecule and/or
indirectly by altering the structure of the HLA molecule and, in
particular, the critical Bw4 motif (38).
To address these possibilities, we solved the binary structure of
HLA-B*57:01 in complex with LF9 E8 (Table 2) and compared
this to the structure of KIR3DL1*001 in complex with HLA-B*57:
01-LF9 (Fig. 1). These data showed that the side chain of glutamic
acid at P8 protruded out of the peptide-binding cleft but did not
significantly alter the Bw4 epitope. However, modeling the ter-
nary interaction revealed both steric and charge-mediated clashes
with KIR3DL1*001, most notably via E282 in the KIR D2 domain
(Fig. 1A).
In contrast to LF9 E8, the sensitivity of KIR3DL1*001 to
alanine substitution at P8 was more puzzling. To explore this
observation further, we determined the ternary structure of
KIR3DL1*001-HLA-B*57:01-LF9.A8 (Fig. 1A and Table 2). This
mutant complex could be superimposed closely on the corre-
sponding wild-type ternary structure, and, again, no conforma-
tional adjustments of the Bw4motif were observed. However, the
alanine residue at P8 was positioned such that it could no longer
contact L166 in the KIR D1 domain. Accordingly, this amino acid
substitution abolishes the only direct peptide interaction with
KIR3DL1*001.
Nonpermissive role for KIR3DS1-like residues is dependent
on both HLA and peptide. KIR3DS1 contains a cluster of amino
acid substitutions not typically found in KIR3DL1 (W138, S163,
R166, and L199) that can limit HLA recognition (24, 25).We used
a panel of tetramers of HLA allotypes presenting a variety of pep-
tides to examine the role of these residues in the context of
KIR3DL1*001. The presence of W138, S163, or R166, but not
L199, strongly inhibited binding to HLA-A*2402 (Fig. 2A and B),
whereas only the R166 mutation impaired binding to HLA-
B*57:01 (Fig. 2C and D). In addition to these allotype-specific
differences, peptide-dependent effects further modulated the
binding sensitivity of KIR3DS1-like mutants. For example, bind-
ing of HLA-A*24:02 refolded with the HIV-derived peptide RW8
(RYPLTFGW; Nef, residues 134 to 141) was unaffected by the
TABLE 2 Data collection and refinement statistics for the HLA-B*57:
01-LF9.E8 binary and KIR3DL1*001-HLA-B*57:01-LF9.A8 ternary
complexes
Parameter
Value(s) for:a
HLA-B*57:01-LF9.E8
KIR3DL1*001-
HLA-B*57:01-LF9.A8
Data collection statistics
Temp (K) 100 100
X-ray source MX2 Australian
synchrotron
MX2 Australian
synchrotron
Space group P21 P1
Cell dimensions (Å)
a, b, c (Å) 65.0, 49.3, 70.0 51.9, 62.0, 65.9
, ,  (°) 102.7e 94.6, 98.6,109.2
Resolution (Å) 40.0–1.90 (2.00–1.90) 40.0–2.30 (2.42–2.30)
Total no. of
observations
126,910 (16,154) 107,830 (14,691)
No. of unique
observations
33,403 (4,631) 29,881 (4,161)
Multiplicity 3.8 (3.5) 3.6 (3.5)
Completeness (%) 97.2 (93.5) 90.6 (84.7)
I/	I 9.3 (1.8) 8.0 (2.5)
Rmerge
b 0.09 (0.82) 0.10 (0.41)
Refinement statistics
No. of nonhydrogen
atoms
Protein 3,105 5,281
Water 265 237
Rfactor
c 0.206 0.216
Rfree
c 0.247 0.257
RMSD from idealityd
Bond length (Å) 0.010 0.004
Bond angle (°) 1.09 1.01
Ramachandran plot (%)
Favored 96.0 97.2
Allowed 4.0 2.8
B factors (Å2)
Avg main chain 28.9 38.2
Avg side chain 35.4 40.2
Avg water 39.8 39.4
a Values in parentheses are for the highest-resolution shell.
b Rmerge
 hkl j |IhkljIhkl |/hkl j Ihklj, where Ihklj is the jth observation of
reflection hkl,I is the mean intensity of all observations of the reflection hkl, hkl is
taken over all reflections, and j is taken over all observations of each reflection.
c Rfactor
 hkl ||Fo| |Fc||/hkl |Fo| for all data excluding the 5% that comprised the
Rfree used for cross-validation, where Fo are amplitudes of the structure factors for the
observed data and Fc are amplitudes of the structure factors calculated from the atomic
model. The summation is carried over all data points hkl included in the model
derivation.
d RMSD, root mean square deviation.
e Value is for .
Peptide Controls KIR3DS1 Engagement
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L199 mutation. In contrast, an appreciable loss of binding to
KIR3DL1*001 was observed with the variant peptide RW8 Y2F,
compounded in the presence of L199, which was not apparent
with the variant peptide RW8 W8A. Similarly, binding of HLA-
B*57:01 refolded with the HIV-derived peptide variant TW10
G9D (TSTLQEQIDW;Gag p24, residues 108 to 117) was substan-
tially reduced relative to that of the wild type. However, the R166
mutant formof KIR3DL1*001 displayed a clear preference for this
variant peptide complexed with HLA-B*57:01, and binding was
significantly higher than that seen with KIR3DL1*001. The role of
KIR3DS1-like residues in ligand engagement is therefore influ-
enced by both components of the pHLA complex.
KIR3DS1-like residues interact to influence peptide specific-
ity. In a complementary set of experiments, we assessed the role
of peptide in HLA binding to modified KIR3DS1. Previously,
we showed that HLA engagement required only a single muta-
tion (W138G) in KIR3DS1 (25); this binding was not seen with
other single reversion mutations including those at position
L166 E282 Y200
F9
A8/E8
a1 a2
L166 E282
Y200
F9
S8
BA
KIR3DL1*001KIR3DL1*001
α2
α1
FIG 1 The role of peptide in KIR3DL1-HLA interactions. (A) The structures of KIR3DL1*001-HLA-B*57:01-LF9.A8 ternary complex and the HLA-B*57:01-
LF9.E8 binary complex were solved to a resolution of 2.3 and 1.9 Å, respectively. (B) The structure of the KIR3DL1*001-HLA-B*57:01-LF9 ternary complex used
for comparison. HLA and KIR are shown in green and blue, respectively; amino acids at position P8 and P9 are highlighted. Solid lines indicate direct contacts;
dashed lines represent water-mediated contacts.
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FIG 2 The nonpermissive role of KIR3DS1-like residues is dependent on both HLA and peptide. (A to D) HEK293T cells were transfected with FLAG-tagged
KIR3DL1*001 or single amino acid variants thereof and stained with individual pHLA class I tetramers as indicated. Results are expressed relative to HLA-A*24:
02-RW8 (A) orHLA-B*57:01-TW10 (C) binding toKIR3DL1*001 or relative to the binding of each tetramer toKIR3DL1*001 (B andD).Data are averaged from
three independent experiments. Error bars represent standard errors of themeans. Binding of each tetramer was compared to that seenwith KIR3DL1*001 using
a one-way ANOVA, followed by a Dunnett’s multiple comparison posttest. *, P 0.05; **, P 0.01; ***, P 0.001.
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166. However, the pattern of peptide reactivity was noticeably
different between this KIR3DS1 variant (3DS1*014) and
KIR3DL1 (Fig. 3). Introduction of a second KIR3DL1-like res-
idue (S163P or R166L) also modified the pattern of reactivity.
For example, KIR3DL1 bound moderately to HLA-B*57:01
complexed with LF9 R8, whereas KIR3DS1 W138G showed no
such binding. In contrast, the further introduction of R166L
generated a KIR3DS1 molecule that engaged HLA-B*57:01-
LF9.R8 robustly. These data suggest that the KIR3DS1-like res-
idues interact in a complex fashion to impair HLA affinity and
modify peptide preferences.
Arginine at position 166 inKIR3DS1 limitsHLA interaction.
To further understand the role of KIR3DS1-like residues, both
individually and in concert, we modeled the interaction of
KIR3DS1 with HLA-B*57:01 based on the structure of KIR3DL1
(Fig. 4). From this model, it emerged that HLA binding is primar-
ily impeded by the presence of R166 in KIR3DS1. In silico, this
substitution causes a steric and charge-mediated clash with R83 in
HLA-B*57:01. The characteristics of this model are consistent
with our finding that the L166R substitution in KIR3DL1 results
in a loss of affinity for a broad range ofHLA-Bw4 allotypes (Fig. 2).
Peptide-dependent binding ofHLA-B*57:01 to KIR3DS1.As
the presence of arginine at position 83 is invariant in all HLA-Bw4
allotypes, the KIR3DS1 R166/HLA R83 clash would be predicted
to limit the interaction of KIR3DS1 with all of these molecules.
However, the presented peptide could potentially induce confor-
mational changes at the HLA interface and impact KIR binding.
To address this possibility, we scanned KIR3DL1 mutants incor-
porating KIR3DS1-like residues with a panel of LF9 peptides with
substitutions at P8. As previously documented, KIR3DL1*001
binding was highly sensitive to P8 residue changes in the HLA-
B*57:01-LF9 complex (12, 37) (Fig. 5A). Overall, the same pattern
of peptide reactivity was observed with theW138, S163, and L199
mutant forms of KIR3DL1*001. In contrast, the R166 mutant in-
teracted substantially with HLA-B*57:01-LF9.F8 despite barely
recognizing the corresponding wild-type complex. These findings
suggest that specific substitutions at P8 might allow KIR3DS1 to
bind HLA-B*57:01. Consistent with this idea, KIR3DS1-express-
ing cells bound tetrameric complexes ofHLA-B*57:01-LF9.F8 but
not HLA-B*57:01-LF9. Moreover, this interaction was abrogated
in the presence of the anti-KIR3DS1 blocking antibody Z27 (Fig.
5B and C). The epitope recognized by the Z27 antibody overlaps
the HLA-binding face and prevents interaction of KIR3DL1 with
its HLA ligand (data not shown).
The binding of HLA-B*57:01-LF9.F8 to KIR3DS1 suggested
that other peptide residues might also be capable of supporting
this interaction. Similar to phenylalanine (F), both tyrosine (Y)
and tryptophan (W) contain an aromatic ring, prompting us to
examine the binding of KIR3DS1 to HLA-B*57:01-LF9.W8 and
HLA-B*57:01-LF9.Y8. Weak binding was observed with both of
these variant pHLA complexes (Fig. 5D) although this was not
statistically significant in the case of Y8, and specificity was again
confirmed by blocking with Z27 (data not shown).
Te
tr
am
er
 B
in
di
ng
S8 A8  E8  F8  H8  L8  R8 S8 A8  E8  F8  H8  L8  R8 S8 A8  E8  F8  H8  L8  R8 S8 A8  E8  F8  H8  L8  R8 
HLA-B*57:01 LSSPVTKSF
*
 
**
 
* **
 ns
***
3DL1
3DS1 W138G
3DS1 W138G + S163P
400
300
200
100
0
3DS1 W138G + R166L
FIG 3 KIR3DS1-specific residues influence peptide specificity. HEK293T cells were transfected with FLAG-tagged KIR3DL1*001 or amino acid variants of
KIR3DS1 and stained with individual HLA-B*57:01-LF9 tetramers incorporating bound peptide substitutions at P8, as indicated. Results are expressed relative
toHLA-B*57:01-LF9 binding for each KIR construct. Data are averaged from three independent experiments. Error bars represent standard errors of themeans.
Binding of L8 and R8 variants of peptide LF9 to each mutant was compared to that seen with KIR3DL1*001 using a one-way ANOVA, followed by a Dunnett’s
multiple comparison posttest. *, P 0.05; **, P 0.01; ***, P 0.001.
α2
α1
FF'hinge
HLA-B*5701 
 
Y200
GA loop
R166
E282
F276
K146
H278
EF loop
3DS1
R83
Y84
peptide
I80 I142
A150
A149S279
FIG4 Modeling of KIR3DS1 residues suggests a steric clash betweenR166 and
HLA-Bw4 R83. Using the structure of KIR3DL1*001-HLA-B*57:01-LF9 for
reference, the KIR3DS1-like R166 residue was modeled in place of the
KIR3DL1 residue L166. HLA and peptide are shown in green and purple,
respectively. KIR is shown in light blue (D1 residues), orange (D2 residues),
and pink (D1-D2 loop). The presence of R166 in KIR3DS1 is predicted to
cause both a steric and a charge clash with R83 in HLA-B57:01.
Peptide Controls KIR3DS1 Engagement
May 2015 Volume 89 Number 10 jvi.asm.org 5217Journal of Virology
 o
n
 M
arch 16, 2016 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
Identification of pathogen-derived peptides that facilitate
HLAbinding toKIR3DS1.The data presented above suggest that,
in the context of HLA-B*57:01, the presence of certain residues at
P8 (F, Y, andW) can facilitate recognition byKIR3DS1. To extend
these findings to a pathogen-relevant context, we explored
peptide databases including the Immune Epitope Database
and Analysis Resource (http://www.iedb.org), SYFPEITHI (http:
//www.syfpeithi.de/), MHCBN (http://www.imtech.res.in/raghava
/mhcbn/index.html), and the Los Alamos National Laboratory
HIVdatabase (http://www.hiv.lanl.gov/content/immunology/). In par-
ticular, we searched for confirmed peptide epitopes that were ei-
ther known to bind HLA-B*57 allotypes or fit the consensus se-
quence for binding to HLA-B*57:01 (P2, A/T/S; P-1, W/F
[where P is the C-terminal anchor position]) (39) that also met
our criteria for binding to KIR3DS1 (P8/P-2, F/W/Y) (Fig. 5).
Based on these specifications, we generated a short list of eight
peptides for further analysis (Fig. 6A). The corresponding pHLA-
B*57:01 tetramers were generated and tested against both LILRB1
and KIR3DS1. Two of the pHLA-B*57:01 complexes refolded
poorly, likely due to low-affinity peptide loading. Of the six re-
maining tetramers, two interacted specifically with KIR3DS1: (i)
AW9 (AAVKAACWW;HIVPol, residues 839 to 847) and (ii) KF9
(KAAFDLSFF; HIVNef, residues 82 to 90). In both cases, binding
was completely inhibited in the presence of Z27 (Fig. 6B).
Activation of KIR3DS1 by pHLA complexes. To determine
whether these pHLA-B*57:01 complexes could generate an acti-
vation signal via KIR3DS1, we used a chimeric KIR3DS1-CD3
Jurkat cell line. These cells were stimulated with plate-bound
pHLA-B*57:01 complexes, and NFAT activity was measured us-
ing a luciferase reporter construct. Cross-linking of KIR3DS1with
the Z27 antibody resulted in robust luciferase activity. Dose-de-
pendent stimulation was also observed with both HLA-B*57:01-
KF9 andHLA-B*57:01-AW9 but not with the control HLA-A*24:
02-RW8 complex (Fig. 6C). These data therefore provide the first
direct evidence of functionally relevant peptide-dependent HLA-
B*57:01 binding to KIR3DS1.
 
 
 
 
0
10
20
30
S8 F8
* 
0
2
4
6
8
10
Te
tr
am
er
 B
in
di
ng
(F
ol
d 
M
FI
)
 
 
S8 F8 W8 Y8
**
*  
B
A
C
D
Te
tr
am
er
 B
in
di
ng
(p
er
ce
nt
ag
e 
po
si
tiv
e 
ce
lls
)
mlgG1
anti-3DS1
S8 A8 E8 F8 H8 L8 R8S8 A8 E8 F8 H8 L8 R8S8 A8 E8 F8 H8 L8 R8S8 A8 E8 F8 H8 L8 R8S8 A8 E8 F8 H8 L8 R8
HLA-B*57:01 LSSPVTKSF
Te
tr
am
er
 B
in
di
ng
Mouse IgG Z27
B
*5
7:
01
 L
SS
PV
TK
FF
B
*5
7:
01
 L
SS
PV
TK
SF
B
*5
7:
01
 L
SS
PV
TK
FF
5.5 38.4
0.8 2.9
3DL1 L166R
3DL1 P199L
3DL1
3DL1 G138W
3DL1 P163S
150
100
50
0
*
FIG 5 The interaction between HLA-B*57:01 and KIR3DS1 is peptide dependent. (A) HEK293T cells were transfected with FLAG-tagged KIR3DL1*001 or
single amino acid variants thereof and stained with individual HLA-B*57:01-LF9 tetramers incorporating bound peptide substitutions at P8, as indicated. Data
are averaged from three independent experiments. Error bars represent standard errors of the means. For KIR3DL1*001 L166R, binding of each peptide variant
was compared to that seen with HLA-B*57:01 LF9 using a one-way ANOVA followed by a Dunnett’s multiple comparison posttest. (B) HEK293 cells were
transfectedwith FLAG-taggedKIR3DS1 and stainedwith eitherHLA-B*57:01-LF9 orHLA-B*57:01-LF9.F8 tetramer in the presence of controlmouse IgG or the
blocking antibody Z27. The frequency of positive cells is depicted in each gate. (C) Data averaged from three independent experiments as shown in panel B.
Binding of each peptide variant was compared to that of LF9 (S8) in the presence of control mouse antibody using a one-way ANOVA followed by a Dunnett’s
multiple comparison posttest. (D) HEK293 cells were transfected with FLAG-tagged KIR3DS1 and stained with individual HLA-B*57:01-LF9 tetramers incor-
porating bound peptide substitutions at P8 as indicated. MFI, median fluorescence intensity. Data are averaged from three independent experiments. Error bars
represent standard errors of the means. Binding of each peptide variant was compared to that of LF9 (S8) using a one-way ANOVA followed by a Dunnett’s
multiple comparison posttest. *, P 0.05; ** P 0.01.
O’Connor et al.
5218 jvi.asm.org May 2015 Volume 89 Number 10Journal of Virology
 o
n
 M
arch 16, 2016 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
DISCUSSION
Numerous studies have associated the presence of particular KIR
genes and KIR/HLA gene combinations with clinical outcomes in
the face of various immune challenges. Although much research
in this area has focused on the ability of KIRs to detect HLA class
I downregulation, also known as “missing self,” the presented
peptide repertoire can also perturb KIR-HLA interactions and
allow for more specific NK cell responses to “altered self.”
To establish the role of KIR residues in the phenomenon of
peptide selectivity, we explored the interaction of KIR3DL1 with
HLA-Bw4using a structure/function-based approach. In linewith
previous evidence, KIR3DL1 binding was critically determined by
amino acid residues at the peptide C terminus. Furthermore, our
data suggest that this effect is governed directly by the ability of
specific C-terminal residues to interact productively with KIR res-
idues rather than indirectly via conformational changes in the
Bw4 epitope. These limitations are imposed by at least two differ-
ent physicochemical characteristics of the relevant peptide resi-
dues, namely, charge and size.
The loss of binding in complexes with small amino acid resi-
dues at P8 may reflect an inability to contact leucine at position
166 in the KIR3DL1D1 domain. Targeting of this KIR residue had
little effect on the interaction with pHLA, however, suggesting
that additional factors contribute to the observed loss of binding.
In this regard, it is notable that the presence of a small amino acid
at this position in the peptide also results in the generation of a
cavity within the structural interface. Such cavities are known to
reduce protein stability (40), which in turn could potentially im-
pact binding affinity. In contrast, our findings suggest that nega-
tively charged residues, as present in the LF9 E8 and TW10 D9
peptides, dramatically disrupt interactions with KIR3DL1. These
results are in line with a previous study (41), which reported that
glutamic acid at P8 impeded KIR3DL1 binding to HLA-B*27:05.
Similarly, another study found that glutamic acid and aspartic
acid at P8 negatively impacted KIR3DL1 binding to two different
pHLA-B*57:03 complexes (36). Our data further suggest that this
intolerance of negatively charged residues relates directly to the
E282 residue present inKIR3DL1. This amino acid lies centrally in
the interaction zone between KIR3DL1 and HLA-B*57:01, and
mutation to the similarly sized but neutral glutamine residue pro-
foundly decreases binding (12). However, perturbation of E282
can also result in unique peptide specificity profiles (37), suggest-
ing additional roles in peptide discrimination beyond the poten-
tial for electrostatic clashes.
Although KIR3DS1 displays a very high degree of similarity to
KIR3DL1 in the extracellular domain, the HLA binding charac-
teristics of this activating receptor are dramatically different. Our
data show that KIR3DS1-specific residues interact to determine
HLA restriction and peptide specificity. One KIR3DS1 residue in
particular (R166) plays a dominant role in the observed lack of
binding to a broad array of pHLA complexes.Molecularmodeling
is consistent with these biochemical findings and predicts a signif-
icant steric and electrostatic clash in hypothetical KIR3DS1-HLA-
Bw4 complexes. Nonetheless, certain peptides can overcome the
effects of this arginine residue in both KIR3DL1 L166R mutants
and wild-type KIR3DS1 molecules. In particular, peptides with
large aromatic residues at P8 allowed weak, but highly reproduc-
ible, binding to KIR3DS1 with sufficient avidity to deliver an ac-
tivation signal. In contrast to phenylalanine, tryptophan, and, to a
lesser extent, tyrosine, the presence of histidine at position 8 did
not facilitate KIR3DS1 binding. This may be due to subtle differ-
ences in the size and orientation of His relative to the size and
orientation of other aromatic amino acids. In addition, at physi-
ological pH, some portion of His residues will be charged, which,
in light of the inhibitory effect of charged peptide residues in
KIR3DL1 interaction, is predicted to disrupt binding. It remains
unclear how the presence of permissive peptide residues over-
comes the negative impact of arginine at position 166. One possi-
bility is that the aromatic rings of these residues stack well with
arginine side chains to promote productive interactions (42), while
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their large size prevents the formation of any destabilizing cavities at
the interface. It is also notable that the rare KIR3DS1*014 allotype,
which incorporates one amino acid change (W138G) but retains
R166, exhibits robust HLA recognition (25). Collectively, these ob-
servations suggest that the normally disruptive effects of R166 can
be circumvented by changes at the KIR3DS1-HLA-Bw4 interface,
occurring either due to the presence of certain HLA-bound pep-
tides or as a consequence ofmutations at neighboring positions in
the KIR3DS1 molecule.
Our findings suggest that the multiple changes in KIR3DS1
are driven to restrict, but not abolish, the capacity of this re-
ceptor to interact with HLA-Bw4. Peptide-specific activation of
KIR3DS1 may therefore only occur when the array of potential
epitopes displayed on a target cell is appropriately altered in the
context of infection, stress, or transformation. Viral infections,
including HIV infection, are known to result in substantial
changes in peptide repertoire due to the presence of peptides
from virally derived proteins, stress-induced proteins (43), and
peptides produced by the immunoproteasome (44). Thus, this
may be a general mechanism for the engagement of both acti-
vating and inhibitory KIR to be modulated in response to viral
infection. Consistent with this notion, we identified two HIV-
derived peptides that enable HLA-B*57:01 to interact with
KIR3DS1. Although not dependent on peptide, in the murine
system Ly49H binding to the murine CMV (MCMV)-derived
m157 protein sets a precedent for such pathogen-dependent
activation (45, 46). Notably, this interaction leads to an expan-
sion of Ly49H NK cells, as has been reported for the
KIR3DS1NK cell subset in HCMV and HIV infection (9, 47).
Although genetic disease association studies suggest a role
for activating KIRs in the outcome of HIV infection and al-
though functional analyses have enhanced our understanding of
KIR3DS1 NK cell responses (8, 9), the lack of identifiable HLA-
Bw4 ligands continues to limit mechanistic insights into the biol-
ogy of these receptors during the disease process. Our work dem-
onstrates for the first time that KIR3DS1 can interact productively
with HLA-Bw4 in the context of HIV infection. By extension,
these data support a model whereby changes in the peptide reper-
toire associated with viral infection provide a trigger for KIR3DS1
engagement and NK cell activation.
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